News Tocilizumab Shortage Prompts Temporary REMS Change for CAR T-Cell Therapy Publish Date December 14, 2021 Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.
Drugs in the Pipeline Baricitinib Alone Authorized for COVID-19 Under Revised EUA Publish Date July 29, 2021 The update was based on data from the COV-BARRIER study.
Drugs in the Pipeline Early Data Show Potential Benefit of Acalabrutinib in Severe COVID-19 Publish Date June 9, 2020 Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.